A Phase II Multi-Center Study of 5-AZA-2'-Deoxycytidine (Decitabine) Single Agent in Taiwanese Patients With Myelodysplastic Syndrome (MDS).
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2013
At a glance
- Drugs Decitabine (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 14 Aug 2013 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 16 Jun 2011 Planned end date changed from 1 Jul 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 01 Apr 2011 Planned End Date changed from 1 Dec 2010 to 1 Jul 2011 as reported by ClinicalTrials.gov.